What's on this Page
What is Teprotumumab
Teprotumumab is an insulin-like growth factor 1 receptor (IGF-1R) inhibitor approved for the treatment of thyroid eye disease.
It is given via intravenous infusion every 3 weeks for a total of 8 doses.
Teprotumumab may cause infusion-related reactions, hyperglycemia, and exacerbation of inflammatory bowel disease.
In utero exposure to teprotumumab may cause fetal harm; therefore, use of the drug during pregnancy should be avoided. Instruct women of child-bearing potential to use effective contraception prior to, during, and for 6 months after treatment with teprotumumab.
Brand Name
TEPEZZA
Indications
- Graves’ ophthalmopathy
- thyroid eye disease
For the treatment of thyroid eye disease (i.e., Graves’ ophthalmopathy or thyroid-associated ophthalmopathy)
Side Effects
- alopecia
- asthenia
- diarrhea
- dysgeusia
- dyspnea
- fatigue
- headache
- hearing loss
- hyperacusis
- hyperglycemia
- hypertension
- inflammatory bowel disease
- infusion-related reactions
- musculoskeletal pain
- nausea
- sinus tachycardia
- xerosis
Monitoring Parameters
- blood glucose
- pregnancy testing
Contraindications
- breast-feeding
- contraception requirements
- diabetes mellitus
- hyperglycemia
- inflammatory bowel disease
- infusion-related reactions
- pregnancy
- reproductive risk
Interactions
There are no drug interactions associated with Teprotumumab products.
